Sagimet Biosciences Inc.
SGMTNasdaqCIK 1400118HealthcareFiscal year ends Dec 31
Latest reported revenue, Q4 FY2023$0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-12, accession 0001558370-25-002747. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Dec 31, 2023, from the 10-K filed Mar 12, 2025.Latest quarter: Q2 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenuenot reported (Revenue not reported)No year-earlier figure to compare
- Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue not reported)No year-earlier figure to compare
- Diluted EPS−$0.26Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.26 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure+18.8% on a year earlier - Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | Q3 FY20242024-09-30 | Q4 FY20242024-12-31 | Q1 FY20252025-03-31 | Q2 FY20252025-06-30 | Q3 FY20252025-09-30 | Q4 FY20252025-12-31 | Q1 FY20262026-03-31 | Q2 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $ | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (0.45)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure | not reported (Diluted EPS not reported) | (0.56)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure | (0.32)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure | (0.40)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure | not reported (Diluted EPS not reported) | (0.33)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure | (0.26)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure | |
| Free cash flow | $ | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY2022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|
| Revenue | $k | not reported (Revenue not reported) | 2,000Revenue, FY2023, twelve months to 2023-12-31$2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-12, accession 0001558370-25-002747.Report this figure | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Revenue not reported) | (1537.0%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$30.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-12, accession 0001558370-25-002747.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-12, accession 0001558370-25-002747.Report this figure | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | (1393.8%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$27.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-12, accession 0001558370-25-002747.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-12, accession 0001558370-25-002747.Report this figure | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (165.20)Diluted EPS, period not labelled, twelve months to 2022-12-31−$165.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-25, accession 0001558370-24-003812.Report this figure | (2.66)Diluted EPS, FY2023, twelve months to 2023-12-31−$2.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-12, accession 0001558370-25-002747.Report this figure | (1.45)Diluted EPS, FY2024, twelve months to 2024-12-31−$1.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-11, accession 0001104659-26-026140.Report this figure | (1.58)Diluted EPS, FY2025, twelve months to 2025-12-31−$1.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-11, accession 0001104659-26-026140.Report this figure | |
| Free cash flow | $k | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2026-06-30 | $50.8m | 6,575,788 | Added+5,775,845 | |
| Balyasny Asset Management L.P. | 2026-06-30 | $28.0m | 3,626,113 | New+3,626,113 | |
| Woodline Partners LP | 2026-06-30 | $23.2m | 3,000,652 | Added+1,999,709 | |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2026-06-30 | $22.6m | 2,927,698 | New+2,927,698 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $19.8m | 2,566,272 | Added+1,467,353 | |
| BVF INC/IL | 2026-06-30 | $19.3m | 2,500,000 | New+2,500,000 | |
| Caligan Partners LP | 2026-06-30 | $19.3m | 2,500,000 | New+2,500,000 | |
| Affinity Asset Advisors, LLC | 2026-06-30 | $19.3m | 2,497,864 | Added+1,629,844 | |
| FEDERATED HERMES, INC. | 2026-06-30 | $16.1m | 2,086,715 | Added+2,085,934 | |
| GREAT POINT PARTNERS LLC | 2026-06-30 | $15.7m | 2,029,933 | New+2,029,933 |
Recent filings
All 260 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2211:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-428314 |
| 2026-10-0122:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-409335 |
| 2026-09-3010:09 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-408224 |
| 2026-08-1311:05 ET | 8-K | 8.01 Other events | 0001193125-26-347854 |
| 2026-08-1111:35 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-343446 |
| 2026-08-1111:30 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-343441 |
| 2026-07-2101:35 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-309334 |
| 2026-06-1220:06 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001104659-26-073431 |
| 2026-06-0320:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-070126 |
| 2026-05-1211:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-059009 |
Latest annual report
Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 11, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1400118
- Tickers
- SGMT
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- DE
- Filer category
- <br>Emerging growth company
- Former names
- 3-V Biosciences, Inc. (to 2019-02-25)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.